Stock Price, News, Quote and Profile of SIO GENE THERAPIES INC(NASDAQ:SIOX) stock

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

SIO GENE THERAPIES INC

NASDAQ:SIOX (3/22/2023, 8:00:04 PM)

After market: 0.4151 +0 (+0.02%)

0.415

+0.01 (+2.09%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS SectorHealth Care

GICS IndustryBiotechnology

Chartmill FA Rating

Valuation

Growth

Profitability

Health

Dividend

Overview

Earnings (Last)

Earnings (Next)

Ins Owners

Inst Owners

Market Cap30.70M

PEN/A

Fwd PEN/A

Dividend YieldN/A

Analysts

IPO

Stock Screener Links

GICS Sector Stock Screener

Find competitors from the same sector on the USA

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

Company Profile

Sio Gene Therapies, Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of gene therapies for neurological diseases. The company is headquartered in New York City, New York and currently employs 12 full-time employees. The company went IPO on 2015-06-11. The firm is focused on pushing the boundaries of gene therapy to develop treatments for debilitating rare neurodegenerative diseases, including GM1 gangliosidosis and Tay-Sachs/Sandhoff disease. The firm is primarily focused on pre-clinical research and development initiatives in gene therapy.

Company Info

SIO GENE THERAPIES INC

1501 Broadway, 12Th Floor

New York City NEW YORK 10036

P: 18777464891.0

CEO: Pavan Cheruvu

Employees: 12

Website: https://siogtx.com/

SIOX News

3 months ago - Sio Gene Therapies, Inc.Sio Gene Therapies, Inc. to File for Dissolution and Declare an Initial Liquidating Distribution of $0.435 Per Share

PARSIPPANY, N.J., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Sio Gene Therapies, Inc. (

a year ago - Sio Gene Therapies, Inc.Sio Gene Therapies Announces Fiscal Third Quarter 2022 Financial Results

– Three-Month and Nine-Month Losses decline by 84.2% and 73.5%, respectively – Operating Cash Outflows for the Nine Months Ended December 31, 2022...

a year ago - Seeking AlphaSio Gene Therapies to dissolve company, liquidate assets (NASDAQ:SIOX)

The board of microcap Sio Gene Therapies (SIOX) has decided to dissolve the company and liquidate its assets following a review of potential strategic alternatives.

a year ago - Sio Gene Therapies, Inc.Sio Gene Therapies Inc. Announces Board Approval of Plan of Complete Liquidation and Dissolution

SIO GENE THERAPIES INC (SIOX)

Nasdaq Stock Screener

USA Stock Screener